Semler Scientific, Inc. Provides Earnings Guidance for the Year 2021 and 2022
November 01, 2021 at 04:09 pm EDT
Share
Semler Scientific, Inc. provided earnings guidance for the year 2021 and 2022. For the remainder of 2021 and in 2022, Semler Scientific expects continued profitability and generation of cash from operating activities. It is Semler Scientific?s intent to grow annual revenues at a faster rate than annual expenses and to remain profitable.
Semler Scientific, Inc. develops, manufactures, and markets products and services that assist in evaluating and treating chronic diseases. The Company provides technology solutions to healthcare providers. The Company's flagship product, QuantaFlo is a four-minute in-office blood flow test. Healthcare providers can use blood flow measurements as part of their examinations of a patientâs vascular condition, including assessments of patients who have vascular disease. QuantaFlo features a sensor clamp that is placed on the toe or finger. Infrared light emitted from the clamp on the dorsal surface of the digit is scattered and reflected by the red blood cells coursing through the area of illumination. Returning light is sensed by the sensor. A blood flow waveform is instantaneously constructed by its proprietary software algorithm. Its customers for QuantaFlo include insurance plans, physician groups, risk assessment groups, hospitals and retailers.
SEMLER SCIENTIFIC, INC. 
